1. Home
  2. IMMR vs PRLD Comparison

IMMR vs PRLD Comparison

Compare IMMR & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$6.12

Market Cap

216.7M

Sector

Technology

ML Signal

HOLD

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$3.29

Market Cap

207.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
PRLD
Founded
1993
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.7M
207.5M
IPO Year
1999
2020

Fundamental Metrics

Financial Performance
Metric
IMMR
PRLD
Price
$6.12
$3.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$13.50
$4.67
AVG Volume (30 Days)
308.9K
225.6K
Earning Date
02-27-2026
03-10-2026
Dividend Yield
4.83%
N/A
EPS Growth
82.69
23.21
EPS
N/A
N/A
Revenue
$35,013,000.00
$12,140,000.00
Revenue This Year
N/A
$320.10
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
73.43
52 Week Low
$5.65
$0.61
52 Week High
$8.15
$4.19

Technical Indicators

Market Signals
Indicator
IMMR
PRLD
Relative Strength Index (RSI) 47.79 56.67
Support Level $5.77 $1.02
Resistance Level $6.39 $4.10
Average True Range (ATR) 0.19 0.33
MACD 0.00 -0.04
Stochastic Oscillator 43.55 39.32

Price Performance

Historical Comparison
IMMR
PRLD

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

Share on Social Networks: